53 Results

FDA approves Balversa to treat bladder cancer

 Added 1 month ago

Johnson & Johnson’s Balversa (erdafitinib) has FDA approval as the first targeted therapy for advanced bladder cancer. Balversa is the...

Early menopause in smokers linked to bladder cancer

 Added 2 months ago

Research shows that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer. 

Phase III OLYMPUS trial of UGN 101 shows positive response in urothelial cancer.- UroGen Pharma.

 Added 4 months ago

UroGen Pharma announced topline results from the ongoing pivotal Phase III OLYMPUS clinical trial of UGN 101 (mitomycin gel) for...

Positive interim data from Phase III VISTA trial of Vicinium to treat bladder cancer.- Sesen Bio

 Added 4 months ago

Sesen Bio reported positive preliminary efficacy data for the primary endpoint of its ongoing Phase III registration trial, the VISTA...

JNJ 42756493 filed with the FDA for metastatic urothelial cancer.- Janssen R&D.

 Added 8 months ago

Janssen Pharmaceutical announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of JNJ 42756493...

FDA restrictions on Keytruda and on Tecentriq for bladder cancer.

 Added 10 months ago

The FDA has restricted use of Keytruda (pembrolizumab) from Merck Inc.and Tecentriq (atezolizumab) from Roche among patients with locally advanced...

EMA warning relating to use of Keytruda and Tecentriq in bladder cancer. Merck Inc. and Roche .

 Added 11 months ago

Early data from two clinical trials ( Keynote-361 and IMvigor130 ) show reduced survival with Keytruda (pembrolizumab) and Tecentriq (atezolizumab)...

FDA warning of deaths in KEYNOTE 361 and IMvigor 130 studies of patients with bladder cancer taking Keytruda or Tecentriq monotherapy. Merck Inc.and Genentech /Roche.

 Added 11 months ago

The FDA on 25 May warned oncologists and clinical trial investigators of early signs from two trials that some bladder...

Successful Phase III VISTA trial of Vicinium to treat high-grade non-muscle invasive bladder cancer . Sesen Bio.Inc.

 Added 11 months ago

Sesen Bio, Inc. (formerly Eleven Biotherapeutics) has announced positive, three-month data from its ongoing Phase III VISTA Trial of Vicinium...

Load more